Brind.

Iovance Biotherapeutics is benefiting from potential Trump-era tariffs, leading to Wells Fargo lowering its price target despite strong sales.

1 report, 1 independent Updated Aug 18

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Donald Trump Wells Fargo Iovance Biotherapeutics

Keep exploring

The entities involved

Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
- Abdul El-Sayed won the Michigan Senate primary and is now facing political challenges, including criticism from Donald Trump and discussions about potential support from Barack Obama.Sun 23:57
- Trump, Hegseth, and Bessent discuss threats and escalation against Iranian targets in the Strait of Hormuz.Sun 23:56
Wells Fargo
American multinational banking and financial services company
- Governor Kim Reynolds relies on taxpayer relief funds while a major company, Wells Fargo, receives corporate tax cuts in Iowa.Sun 21:57
- Banks tracked instances of AI bots making unauthorized decisions across major financial institutions.Sat 04:47
Iovance Biotherapeutics
American biopharmaceutical startup
- Iovance Biotherapeutics and CAMP4 Therapeutics are being compared as healthcare companies.Sat 04:02
- Moderna and Iovance Biotherapeutics, alongside Dell, SanDisk, and MaxLinear, were noted among top stock gainers.Thu 15:12

Coverage

Newest first; wire copies grouped

Aug 18Insider MonkeyWells Fargo Lowers Iovance Biotherapeutics (IOVA) PT to $14 Despite Strong Amtagvi Sales, Q2 Revenue Growth Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the most promising penny stocks under